FibroGen Inc (NASDAQ:FGEN) shares traded up 6.7% during mid-day trading on Tuesday . The company traded as high as $53.50 and last traded at $53.25. 684,543 shares changed hands during trading, an increase of 30% from the average session volume of 527,060 shares. The stock had previously closed at $49.90.

A number of research analysts recently issued reports on the company. BidaskClub upgraded FibroGen from a “sell” rating to a “hold” rating in a research note on Thursday, December 21st. ValuEngine downgraded FibroGen from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Finally, Mizuho assumed coverage on FibroGen in a research note on Wednesday, October 4th. They set a “neutral” rating and a $61.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $65.67.

The firm has a market capitalization of $4,380.00, a P/E ratio of -26.23 and a beta of 1.55. The company has a current ratio of 10.83, a quick ratio of 10.83 and a debt-to-equity ratio of 0.16.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.50) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.37) by ($0.13). FibroGen had a negative return on equity of 47.36% and a negative net margin of 120.00%. equities analysts predict that FibroGen Inc will post -1.75 earnings per share for the current fiscal year.

In related news, CEO Thomas B. Neff sold 38,636 shares of the business’s stock in a transaction that occurred on Tuesday, October 31st. The stock was sold at an average price of $56.13, for a total value of $2,168,638.68. Following the transaction, the chief executive officer now directly owns 3,144,573 shares of the company’s stock, valued at approximately $176,504,882.49. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Thomas B. Neff sold 18,900 shares of the business’s stock in a transaction that occurred on Friday, December 28th. The stock was sold at an average price of $48.29, for a total value of $912,681.00. Following the completion of the transaction, the chief executive officer now directly owns 3,071,705 shares in the company, valued at $148,332,634.45. The disclosure for this sale can be found here. Over the last three months, insiders sold 295,346 shares of company stock worth $14,152,764. 13.60% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of FGEN. FMR LLC lifted its holdings in FibroGen by 96.9% in the 2nd quarter. FMR LLC now owns 3,335,997 shares of the biopharmaceutical company’s stock worth $107,753,000 after purchasing an additional 1,641,423 shares in the last quarter. EcoR1 Capital LLC lifted its holdings in FibroGen by 3,674.1% in the 2nd quarter. EcoR1 Capital LLC now owns 1,585,457 shares of the biopharmaceutical company’s stock worth $51,210,000 after purchasing an additional 1,543,448 shares in the last quarter. Janus Henderson Group PLC purchased a new position in FibroGen in the 2nd quarter worth approximately $45,633,000. Eagle Asset Management Inc. purchased a new position in FibroGen in the 3rd quarter worth approximately $46,158,000. Finally, Vanguard Group Inc. lifted its holdings in FibroGen by 15.1% in the 2nd quarter. Vanguard Group Inc. now owns 5,808,439 shares of the biopharmaceutical company’s stock worth $187,612,000 after purchasing an additional 761,421 shares in the last quarter. 57.23% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “FibroGen (FGEN) Trading 6.7% Higher” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/01/24/fibrogen-fgen-trading-6-7-higher.html.

FibroGen Company Profile

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.